CN114073716A - Medical application of monascus in preparation of anticoccidial drugs and preparation thereof - Google Patents
Medical application of monascus in preparation of anticoccidial drugs and preparation thereof Download PDFInfo
- Publication number
- CN114073716A CN114073716A CN202010808749.4A CN202010808749A CN114073716A CN 114073716 A CN114073716 A CN 114073716A CN 202010808749 A CN202010808749 A CN 202010808749A CN 114073716 A CN114073716 A CN 114073716A
- Authority
- CN
- China
- Prior art keywords
- monascus
- preparation
- medical application
- mycelium
- coccidiosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000228347 Monascus <ascomycete fungus> Species 0.000 title claims abstract description 29
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000001165 anti-coccidial effect Effects 0.000 title claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims abstract description 17
- 230000004151 fermentation Effects 0.000 claims abstract description 17
- 244000113306 Monascus purpureus Species 0.000 claims abstract description 10
- 235000002322 Monascus purpureus Nutrition 0.000 claims abstract description 10
- 229940057059 monascus purpureus Drugs 0.000 claims abstract description 10
- 208000003495 Coccidiosis Diseases 0.000 claims description 21
- 206010023076 Isosporiasis Diseases 0.000 claims description 21
- 241000287828 Gallus gallus Species 0.000 abstract description 21
- 241001465754 Metazoa Species 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 230000002924 anti-infective effect Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 229960005486 vaccine Drugs 0.000 abstract description 2
- 235000013330 chicken meat Nutrition 0.000 description 20
- 230000000694 effects Effects 0.000 description 11
- 210000003746 feather Anatomy 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 244000061456 Solanum tuberosum Species 0.000 description 6
- 235000002595 Solanum tuberosum Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000031003 Monascus ruber Species 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 210000003250 oocyst Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 241000235349 Ascomycota Species 0.000 description 2
- 240000007165 Eragrostis tenella Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Abstract
The invention discloses a medical application of monascus in preparation of anticoccidial drugs and a preparation thereof, and discloses a new medical application of monascus, fermentation broth and mycelium, in particular an application in preparation of anticoccidial drugs for animals such as chicken and the like. The fermentation liquor and mycelium of the monascus purpureus related by the invention are nontoxic and have high safety; overcomes the defects of using chemical drugs or using vaccines in the prior art in the industry, and has the advantages of weight increment and good anti-infection performance.
Description
Technical Field
The invention discloses a medical application of monascus in preparation of coccidiosis resistant medicines, is a new medical application, can be used as a novel feed or drinking water additive for resisting coccidiosis of animals such as chickens, and belongs to the technical field of poultry microecological preparations.
Background
Coccidiosis is an important protozoal disease of animals, and chicken coccidiosis is an important parasitic disease which is caused by the fact that various coccidia of Eimeria are parasitized in chicken intestinal tracts and endangers the development of the chicken industry. For years, the main means for controlling chicken coccidiosis is chemical drugs, and although the drugs play an important role in preventing and treating the chicken coccidiosis, the chicken coccidiosis still faces the threat of coccidiosis outbreak due to the emergence of drug-resistant insect strains. In addition, chemical drugs inevitably cause residues in chicken and eggs, which presents a great potential hazard to human health. In order to solve the problems, people mainly turn to Chinese herbal medicines and immunity to prevent and treat chicken coccidiosis.
Although researches find that some anticoccidial traditional Chinese medicines have the advantages of small toxic and side effects, improvement of disease resistance of organisms, difficulty in generating drug resistance and the like, the traditional Chinese medicines have the defects of slow effect taking and the like.
Monascus purpureus went (f) according to the present inventionMonascus purpureus Went) was named as monascus belonging to the phylum mycosis, class ascomycetes, genus monascus. The production and the use in China have been over 1000 years old. Monascus is the only important microorganism approved to be used for producing edible pigment in the world at present as the fermentation strain of traditional Chinese food. The effect of the compound in resisting parasites is not reported in relevant documents after retrieval.
Disclosure of Invention
The invention provides a medical application of monascus in preparation of anti-coccidiosis drugs, which is a new medical application and is used for preventing and treating coccidiosis caused by coccidiosis of animals such as chickens.
Monascus purpureus went (Monascus purpureus Went) alias monascus, belonging to the phylum mycomycota, class ascomycetes, genus monascus, including monascus fermentation broth and mycelium.
The invention adopts the following technical scheme: selecting Monascus ruber (AS 3.554) colony cultured on PDA culture medium, inoculating in potato juice (PDA) liquid culture medium, culturing at 30 deg.C for 7-10 days, centrifuging after the color turns red to obtain Monascus ruber fermentation liquid and mycelium respectively (see figure 1). Then, the monascus fermentation liquid and the thalli with different dosages are respectively used for carrying out coccidiosis resistance tests to obtain the optimal using amount. The feed used during the test was corn flour without any antibiotic addition.
The invention has the positive effects that:
discloses a new medical application of monascus purpureus, fermentation liquor and mycelium, in particular to an application in preparing drugs for resisting animal coccidiosis such as chicken and the like. The fermentation liquor and mycelium of the monascus purpureus related by the invention are nontoxic and have high safety; overcomes the defects of using chemical drugs or using vaccines in the prior art in the industry, and has the advantages of weight increment and good anti-infection performance.
Drawings
FIG. 1 shows a culture solution of Monascus purpureus of the present invention.
Detailed Description
The following describes specific embodiments of the present invention, but it will be understood by those skilled in the art that this is by way of example only and that the scope of the present invention is defined by the appended claims, and those skilled in the art can make various changes or modifications to these embodiments without departing from the principle and spirit of the present invention, and these changes and modifications fall within the scope of the present invention.
Example 1
Preparing a PDA culture medium:
taking 1L of potato juice, adding 10g of glucose, and adjusting pH to 6.0. The solid culture medium needs to be added with 2% agar. And (3) sterilization conditions: 115 ℃ for 30 min.
Example 2
Potato juice (PDA) medium:
peeling fresh potato, cutting into small pieces, adding 200g of distilled water, boiling with electromagnetic oven with strong fire, and timing with slow fire for 1 hr. Filtering with gauze (8 layers), and adding distilled water to make up to 1L to obtain the desired potato juice.
Example 3
Inoculating and culturing monascus:
monascus ruber (AS 3.554) is streaked on PDA culture medium, and then 4-5 blocks of Monascus ruber colonies cultured on PDA culture medium with size of 1 square centimeter are taken by a needle tube of a sterile injector and placed in 500ml potato juice (PDA) liquid culture medium. Culturing at 30 deg.C for 7-10 days with a shaking table at 150r/min until the color becomes dark red (see figure 1).
Example 4
Preparing monascus fermentation broth use liquid:
centrifuging the culture solution of example 3 at 3000r/min to obtain supernatant, which is Monascus fermentation broth, and diluting 50ml of Monascus fermentation broth stock solution to 500ml to obtain Monascus fermentation broth use solution for use.
Example 5
Preparation of monascus mycelium use solution:
centrifuging the culture solution of example 3 at 3000r/min, precipitating to obtain Monascus mycelium, and diluting 50ml of Monascus mycelium stock solution to 500ml to obtain Monascus mycelium use solution.
The medical use of the present invention is demonstrated by the following test examples
Test example 1
The anti-chicken coccidiosis effect of the monascus fermentation liquid is as follows:
75 SPF chickens of one day age are selected to be bred in a disinfected animal house and are randomly divided into 5 groups of 15, wherein 1-3 groups are experimental groups treated by the invention, 4 groups are groups not treated by the pests, and 5 groups are blank control groups. Weight-per-feather recording and insect-attack testing was performed at 14 days of age, with 10 million E.tenella (E.tenella) for each of 1-4 groups of SPF chickensE.tenella) The oocysts/feathers are infected through mouth, 1 to 3 groups of chickens are respectively subjected to oral intragastric lavage according to monascus fermentation liquor with the dosages of 0.5 ml/feather, 1 ml/feather and 2 ml/feather of the use solution in example 4 from 15 days of age, the continuous 7 days are carried out, all the chickens are cut open and killed one by one at 21 days of age, and the anti-coccidiosis ACI index is measured; the grouping, dosing regimen and ACI index are shown in table 1.
TABLE 1 anti-Coccidium Effect of Monascus ruber fermentation broth
| Group of | Dose/plume | Survival rate% | Relative rate of increase in weight% | Value of the disease | Oocyst value | ACI |
| 1 | 0.5 | 100 | 81.24 | 18 | 5 | 158.24 |
| 2 | 1 | 100 | 94.81 | 16 | 1 | 177.81 |
| 3 | 2 | 100 | 119.07 | 10 | 1 | 208.07 |
| 4 | 0 | 100 | 58.2 | 20 | 20 | 118.2 |
| 5 | 0 | 100 | 100 | 0 | 0 | 200 |
And (4) conclusion:
as can be seen from Table 1, the Monascus fermentation broth had a weight gain effect. Has good chicken coccidiosis resisting effect at the dose of 2 ml/feather.
Test example 2
The monascus purpureus mycelium has the effect of resisting chicken coccidiosis:
75 SPF chickens of one day age are selected to be bred in a disinfected animal house and are randomly divided into 5 groups of 15, wherein 1-3 groups are experimental groups treated by the invention, 4 groups are groups not treated by the pests, and 5 groups are blank control groups. Each feather was weighed and tested for attack at 14 days of age, 1-4 groups of SPF chickens were each orally infected with 10 ten thousand oocysts/feather, 1-3 groups of SPF chickens were each orally gavaged at 15 days of age using the monascus mycelia of example 5 at doses of 0.5 ml/feather, 1 ml/feather and 2 ml/feather, and all chickens were individually killed at 21 days of age and tested for anti-coccidiosis ACI index. The grouping, dosing regimen and ACI index are shown in table 2.
TABLE 2 anti-Coccidium Effect of Monascus mycelium
| Group of | Dose/plume | Survival rate% | Relative rate of increase in weight% | Value of the disease | Oocyst value | ACI |
| 1 | 0.5 | 100 | 67.33 | 10 | 5 | 152.33 |
| 2 | 1 | 100 | 80.74 | 10 | 1 | 169.74 |
| 3 | 2 | 100 | 84.57 | 16 | 1 | 167.57 |
| 4 | 0 | 100 | 58.2 | 20 | 20 | 118.2 |
| 5 | 0 | 100 | 100 | 0 | 0 | 200 |
And (4) conclusion:
as can be seen from Table 2, the Monascus mycelium had a weight-increasing effect and had a good anti-coccidiosis effect at a dose of 1 ml/feather.
Claims (2)
1. The medical application of monascus in preparing anticoccidial drugs.
2. The medical use of the monascus purpureus of claim 1 in the preparation of drugs against coccidiosis, wherein the monascus purpureus comprises fermentation broth and mycelium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010808749.4A CN114073716A (en) | 2020-08-12 | 2020-08-12 | Medical application of monascus in preparation of anticoccidial drugs and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010808749.4A CN114073716A (en) | 2020-08-12 | 2020-08-12 | Medical application of monascus in preparation of anticoccidial drugs and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114073716A true CN114073716A (en) | 2022-02-22 |
Family
ID=80280237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010808749.4A Pending CN114073716A (en) | 2020-08-12 | 2020-08-12 | Medical application of monascus in preparation of anticoccidial drugs and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114073716A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105169236A (en) * | 2015-08-27 | 2015-12-23 | 格特生物制药（天津）有限公司 | Fermented traditional Chinese medicine preparation for treating enteritis in chickens |
| CN105431539A (en) * | 2013-05-02 | 2016-03-23 | 荷兰Dna生物科技有限公司 | Novel organic acid pathway |
| CN109430169A (en) * | 2019-01-03 | 2019-03-08 | 江苏强农农业技术服务有限公司 | A kind of ecology beef cattle ground-above type environment protection health cultural method |
-
2020
- 2020-08-12 CN CN202010808749.4A patent/CN114073716A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105431539A (en) * | 2013-05-02 | 2016-03-23 | 荷兰Dna生物科技有限公司 | Novel organic acid pathway |
| CN105169236A (en) * | 2015-08-27 | 2015-12-23 | 格特生物制药（天津）有限公司 | Fermented traditional Chinese medicine preparation for treating enteritis in chickens |
| CN109430169A (en) * | 2019-01-03 | 2019-03-08 | 江苏强农农业技术服务有限公司 | A kind of ecology beef cattle ground-above type environment protection health cultural method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104814985B (en) | A kind of application of algal polysaccharides | |
| Manilal et al. | In vivo therapeutic potentiality of red seaweed, Asparagopsis (Bonnemaisoniales, Rhodophyta) in the treatment of Vibriosis in Penaeus monodon Fabricius | |
| CN106318880B (en) | One bacillus amyloliquefaciens, bacteriostatic agent prepared therefrom and purposes | |
| CN102988981B (en) | Adjuvant for improving immunization effect of Edwardsiella vaccine and use method of adjuvant | |
| CN102154176B (en) | Turbot pathogenic strain and inactivated vaccine for ascites disease | |
| Sivagnanavelmurugan et al. | Effect of Sargassum wightii fucoidan on growth and disease resistance to Vibrio parahaemolyticus in Penaeus monodon post‐larvae | |
| Kongchum et al. | Effect of green tea extract on Vibrio parahaemolyticus inhibition in pacific white shrimp (Litopenaeus vannamei) postlarvae | |
| AftabUddin et al. | Effects of seaweeds extract on growth, survival, antibacterial activities, and immune responses of Penaeus monodon against Vibrio parahaemolyticus | |
| CN103431190B (en) | Immunopotentiator for young portunus trituberculatus and application thereof | |
| CN113604441B (en) | Broad-spectrum phage for rapidly lysing escherichia coli of livestock and poultry and application thereof | |
| Hu et al. | Effect of anticoccidials and antibiotics on the control of blackhead disease in broiler breeder pullets | |
| Wahjuningrum et al. | Feeding duration of dietary Nodulisporium sp. KT29 to prevent the infection of Vibrio harveyi on Pacific white shrimp Litopenaeus vannamei. | |
| CN110959750A (en) | Application of yeast cell wall in field of antibacterial agent for fishing | |
| CN114073716A (en) | Medical application of monascus in preparation of anticoccidial drugs and preparation thereof | |
| CN105012946A (en) | Pasteurellosis and duck colibacilosis combined propolis inactivated vaccine and preparation method thereof | |
| Novita et al. | Potential of Bacillus sp., as a producer of AHL lactonase and its application as a probiotic for the prevention of Mas in catfish (Clarias gariepinus) | |
| KR20110042531A (en) | Preparation of complex products and treatment agent used herb extract for growth inhibition of fisheries pathogenic and marine virus | |
| Shah et al. | Control of fowl typhoid using tissue culture medium waste after harvest of Korean wild ginseng (Panax ginseng) | |
| Mitrovic | Chemotherapeutic efficacy of sulfadimethoxine against fowl cholera and infectious coryza | |
| Edgar et al. | Efficacy of Stenorol®(Halofuginone): III. For the Control of Coccidiosis in Turkeys | |
| CN114209732B (en) | Medicine for preventing and treating nocardiosis and application thereof | |
| CN111154678B (en) | Horse abortion salmonella donkey source strain and application thereof in preparation of donkey paratyphoid inactivated vaccine | |
| CN103966120B (en) | Bacillus sp. and application of bacillus sp. in preparing antibacterial drugs | |
| CN103740624A (en) | Bacillus pumilus and application thereof to preparation of exopolysaccharides | |
| CN112426522B (en) | Pelteobagrus fulvidraco mixed bacteria inactivated vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220222 |